tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Alkermes (ALKS), Viking Therapeutics (VKTX) and Kinnate Biopharma (KNTE)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alkermes (ALKSResearch Report), Viking Therapeutics (VKTXResearch Report) and Kinnate Biopharma (KNTEResearch Report).

Alkermes (ALKS)

In a report released today, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on Alkermes, with a price target of $32.00. The company’s shares closed last Wednesday at $27.83.

According to TipRanks.com, Tsao is a 2-star analyst with an average return of 0.4% and a 39.1% success rate. Tsao covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Cerevel Therapeutics Holdings, and Praxis Precision Medicines.

Alkermes has an analyst consensus of Hold, with a price target consensus of $30.25, representing a 3.9% upside. In a report released yesterday, Stifel Nicolaus also maintained a Hold rating on the stock with a $28.00 price target.

See today’s best-performing stocks on TipRanks >>

Viking Therapeutics (VKTX)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Viking Therapeutics, with a price target of $21.00. The company’s shares closed last Wednesday at $3.18.

According to TipRanks.com, Pantginis has 0 stars on 0-5 stars ranking scale with an average return of -27.8% and a 22.0% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Genenta Science SpA Sponsored ADR, Applied Genetic Technologies, and Bioline RX Ltd Sponsored ADR.

Currently, the analyst consensus on Viking Therapeutics is a Strong Buy with an average price target of $15.50, representing a 369.7% upside. In a report issued on July 19, Maxim Group also assigned a Buy rating to the stock with a $10.00 price target.

Kinnate Biopharma (KNTE)

In a report released today, Robert Burns from H.C. Wainwright initiated coverage with a Buy rating on Kinnate Biopharma and a price target of $33.00. The company’s shares closed last Wednesday at $12.04.

According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -19.2% and a 27.4% success rate. Burns covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Black Diamond Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Kinnate Biopharma with a $31.25 average price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALKS:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More